|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARHGEF10 |
Gene summary for ARHGEF10 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARHGEF10 | Gene ID | 9639 |
| Gene name | Rho guanine nucleotide exchange factor 10 | |
| Gene Alias | GEF10 | |
| Cytomap | 8p23.3 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | O15013 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9639 | ARHGEF10 | PTC01 | Human | Thyroid | PTC | 2.94e-09 | 1.79e-01 | 0.1899 |
| 9639 | ARHGEF10 | PTC04 | Human | Thyroid | PTC | 2.72e-08 | 1.80e-01 | 0.1927 |
| 9639 | ARHGEF10 | PTC05 | Human | Thyroid | PTC | 2.27e-12 | 3.97e-01 | 0.2065 |
| 9639 | ARHGEF10 | PTC06 | Human | Thyroid | PTC | 1.04e-09 | 3.11e-01 | 0.2057 |
| 9639 | ARHGEF10 | PTC07 | Human | Thyroid | PTC | 3.43e-13 | 2.35e-01 | 0.2044 |
| 9639 | ARHGEF10 | ATC11 | Human | Thyroid | ATC | 3.71e-05 | 3.62e-01 | 0.3386 |
| 9639 | ARHGEF10 | ATC12 | Human | Thyroid | ATC | 1.03e-18 | 3.27e-01 | 0.34 |
| 9639 | ARHGEF10 | ATC13 | Human | Thyroid | ATC | 9.67e-16 | 2.86e-01 | 0.34 |
| 9639 | ARHGEF10 | ATC2 | Human | Thyroid | ATC | 5.90e-10 | 7.12e-01 | 0.34 |
| 9639 | ARHGEF10 | ATC3 | Human | Thyroid | ATC | 4.97e-10 | 5.12e-01 | 0.338 |
| 9639 | ARHGEF10 | ATC4 | Human | Thyroid | ATC | 3.44e-20 | 3.71e-01 | 0.34 |
| 9639 | ARHGEF10 | ATC5 | Human | Thyroid | ATC | 6.75e-20 | 3.08e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:006157210 | Cervix | CC | actin filament bundle organization | 44/2311 | 161/18723 | 2.08e-07 | 9.34e-06 | 44 |
| GO:005101710 | Cervix | CC | actin filament bundle assembly | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:190290510 | Cervix | CC | positive regulation of supramolecular fiber organization | 50/2311 | 209/18723 | 2.55e-06 | 7.54e-05 | 50 |
| GO:005149510 | Cervix | CC | positive regulation of cytoskeleton organization | 50/2311 | 226/18723 | 2.53e-05 | 4.29e-04 | 50 |
| GO:003223110 | Cervix | CC | regulation of actin filament bundle assembly | 28/2311 | 105/18723 | 5.19e-05 | 7.79e-04 | 28 |
| GO:011002010 | Cervix | CC | regulation of actomyosin structure organization | 27/2311 | 100/18723 | 5.55e-05 | 8.10e-04 | 27 |
| GO:00069846 | Cervix | CC | ER-nucleus signaling pathway | 16/2311 | 46/18723 | 7.12e-05 | 9.90e-04 | 16 |
| GO:005149210 | Cervix | CC | regulation of stress fiber assembly | 25/2311 | 91/18723 | 7.59e-05 | 1.04e-03 | 25 |
| GO:00310329 | Cervix | CC | actomyosin structure organization | 43/2311 | 196/18723 | 1.11e-04 | 1.40e-03 | 43 |
| GO:003003810 | Cervix | CC | contractile actin filament bundle assembly | 27/2311 | 106/18723 | 1.63e-04 | 1.94e-03 | 27 |
| GO:004314910 | Cervix | CC | stress fiber assembly | 27/2311 | 106/18723 | 1.63e-04 | 1.94e-03 | 27 |
| GO:00322339 | Cervix | CC | positive regulation of actin filament bundle assembly | 18/2311 | 63/18723 | 4.39e-04 | 4.39e-03 | 18 |
| GO:00514966 | Cervix | CC | positive regulation of stress fiber assembly | 14/2311 | 52/18723 | 3.39e-03 | 2.20e-02 | 14 |
| GO:0007015 | Colorectum | AD | actin filament organization | 167/3918 | 442/18723 | 1.65e-16 | 7.94e-14 | 167 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARHGEF10 | SNV | Missense_Mutation | rs768961111 | c.1621N>C | p.Glu541Gln | p.E541Q | O15013 | protein_coding | deleterious(0) | possibly_damaging(0.843) | TCGA-A2-A0SY-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | arimidex | SD |
| ARHGEF10 | SNV | Missense_Mutation | c.464N>A | p.Cys155Tyr | p.C155Y | O15013 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.93) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGEF10 | SNV | Missense_Mutation | rs201516531 | c.4039C>T | p.Arg1347Trp | p.R1347W | O15013 | protein_coding | deleterious(0) | possibly_damaging(0.9) | TCGA-AC-A23C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | chemo | CR |
| ARHGEF10 | SNV | Missense_Mutation | novel | c.2893N>A | p.Glu965Lys | p.E965K | O15013 | protein_coding | tolerated(0.12) | benign(0.418) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARHGEF10 | SNV | Missense_Mutation | c.203N>A | p.Arg68Lys | p.R68K | O15013 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.648) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ARHGEF10 | insertion | Nonsense_Mutation | novel | c.2017_2018insGTTATTGCATCTAATATTCATTAT | p.Met673delinsSerTyrCysIleTerTyrSerLeuLeu | p.M673delinsSYCI*YSLL | O15013 | protein_coding | TCGA-A2-A0CM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD | ||
| ARHGEF10 | insertion | In_Frame_Ins | novel | c.1135_1136insGGATCACATATAATACCATAAATGGGG | p.Ser379delinsTrpIleThrTyrAsnThrIleAsnGlyAla | p.S379delinsWITYNTINGA | O15013 | protein_coding | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ARHGEF10 | SNV | Missense_Mutation | rs756284082 | c.2498N>T | p.Thr833Met | p.T833M | O15013 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ARHGEF10 | SNV | Missense_Mutation | novel | c.2948G>C | p.Arg983Thr | p.R983T | O15013 | protein_coding | tolerated(0.21) | benign(0.164) | TCGA-VS-A954-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| ARHGEF10 | SNV | Missense_Mutation | rs139046783 | c.1048N>A | p.Val350Met | p.V350M | O15013 | protein_coding | tolerated(1) | benign(0.04) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |